Nov 27, 2017 — Accelerate Diagnostics, Inc. has teamed up with Sepsis Alliance for #GivingTuesday, November 28th, a global day of giving that harnesses the collective power of individuals, communities and organizations to encourage philanthropy and to celebrate generosity worldwide. Accelerate Diagnostics has pledged to match the first $10,000 gifted to Sepsis Alliance on #GivingTuesday to help raise awareness […]
Nov 16, 2017 — Dr. Watts has held a number of clinical and administrative leadership positions at two renowned academic medical centers, Northwestern (Feinberg School of Medicine, Northwestern Memorial Hospital) and the University of Michigan, and with his training and extensive clinical career as a Pulmonary-Critical Care specialist, he adds a comprehensive background of clinical practice and healthcare administration to […]
Nov 09, 2017 — Dr. Margie Morgan, Scientific Director Microbiology at Cedars-Sinai Medical Center, is scheduled to present on the impact that fast phenotypic antibiotic susceptibility results have to laboratory workflow and patient outcomes at the LabRoots Clinical Diagnostics and Research Virtual Event, November 9th at 12:30 p.m. ET.
Nov 02, 2017 — Accelerate Diagnostics, Inc. today announced preliminary financial results for the quarter ending September 30, 2017. The company further reported signed agreements for 295 instruments year to date; contracts for customer evaluations total 239 instruments while revenue generating placements grew to 56 across the U.S., European, and Middle East regions.
Oct 17, 2017 — Accelerate Diagnostics, Inc. will announce third quarter 2017 financial results at the close of U.S. financial markets on Thursday, November 2, 2017.
Jul 31, 2017 — Accelerate Diagnostics, Inc. announced today the addition of Romney Humphries, PhD, D(ABMM), M(ASCP) to its executive management team as Chief Scientific Officer.
Jun 15, 2017 — Accelerate Diagnostics, Inc. showcased new data presented at ASM Microbe 2017 on the potential clinical and workflow benefits of faster susceptibility results using the Accelerate Pheno™ system and Accelerate PhenoTest™ BC kit.
May 30, 2017 — Accelerate Diagnostics, Inc. today announced that new data from 11 healthcare institutions covering more than 1,200 samples will be presented at the upcoming annual meeting of the American Society for Microbiology – ASM Microbe in New Orleans, LA.
May 15, 2017 — Accelerate Diagnostics, Inc. (Nasdaq:AXDX) announced the closing of its previously announced underwritten public offering of 2,750,000 shares of its common stock today, upsized from the original share offering of 2,500,000 shares of common stock, at a previously disclosed public offering price of $28.85 per share. The gross proceeds to Accelerate Diagnostics from the offering are approximately $79.3 million before deducting underwriting commissions and discounts, and estimated offering expenses payable by the company.
May 03, 2017 — Accelerate Diagnostics, Inc. today announced preliminary financial results for the quarter ending March 31, 2017 including signed customer evaluation contracts covering 169 instruments, 22 additional instruments converted into revenue generating placements, and revenue growth exceeding 325% of the same period in the prior year.